Effects of azoles on human acute myelogenous leukemia blasts and T lymphocytes derived from acute leukemia patients with chemotherapy-induced cytopenia

International Immunopharmacology

Volumn 1, Issue 12, 2001, Pages 2183-2195

  Bruserud, O ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Acute myelogenous leukemia; Fluconazole; Itraconazole; Ketoconazole; Miconazole; T lymphocytes

Indexed keywords

ANTILEUKEMIC AGENT; CYTOKINE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; PYRROLE DERIVATIVE;

ACCESSORY CELL; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; BLAST CELL; CELL ACTIVATION; CELL FUNCTION; CELL PROLIFERATION; CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOPENIA; DISEASE PREDISPOSITION; DRUG EFFECT; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOCYTE PROLIFERATION; MALE; MYCOSIS; PRIORITY JOURNAL; PROPHYLAXIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CLONE CELLS; FEMALE; FLUCONAZOLE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-4; ITRACONAZOLE; KETOCONAZOLE; LEUKEMIA, MYELOID; LEUKOPENIA; LYMPHOCYTE ACTIVATION; MALE; MICONAZOLE; MIDDLE AGED; T-LYMPHOCYTES; TUMOR STEM CELLS;

EID: 0034769376     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(01)00145-X     Document Type: Article

References (46)

1. Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients
2. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies
3. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy
4. Prevention of fungal sepsis with prolonged neutropenia: A randomized, double-blind, placebo-controlled trial of intravenous miconazole
5. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia
6. A multicenter randomized trial of fluconazole versus amphothericin B for empirical antifungal therapy of febrile neutropenic patients with cancer
7. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia
8. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission
9. Early allogeneic bone marrow transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia
10. Intensive postremission chemotherapy in adults with acute myeloid leukemia
11. HLA-identical sibling bone marrow transplants vs. chemotherapy for acute myelogenous leukemia in first remission
12. Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: Possible implications for future therapeutic strategies
13. Human CD4 T lymphocytes specifically recognize the fusion region of the hybride protein pml/RARa present in acute promyelocytic leukemia cells
14. BCR/ABL leukemia oncogen fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors
15. Recognition of BCR-ABL positive leukemia blasts by human CD4+ T cell elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide
16. Interleukin 4 responses in acute leukemia patients with severe chemotherapy-induced leucopenia
17. T lymphocyte functions in acute leukemia patients with severe chemotherapy-induced cytopenia: Characterization of clonogenic T cell proliferation
18. Cellular immune responses in acute leukaemia patients with severe chemotherapy-induced leucopenia: Characterization of the cytokine repertoire of clonogenic T cells
19. Interleukin 2 and leukemia
20. The effects of the antifungal azoles itraconazole, fluconazole, ketoconazole and miconazole on cytokine gene expression in human lymphoid cells
21. Comparison of the immunosuppressive activities of the antimycotic agents itraconazole, fluconazole, ketoconazole and miconazole on human T cells
22. New strategies in the treatment of acute myelogenous leukemia (AML): In vitro culture of AML cells - The present use in experimental studies and the possible importance for future therapeutic approaches
23. Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia
24. In vitro culture of acute myelogenous leukemia blasts: A comparison of four different culture media
25. Analysis of MHC class II-specific T cell clones
26. IL2- and IL4-dependent proliferation of T cell clones derived early after allogeneic bone marrow transplantation: Studies of patients with chronic myelogenous leukemia
27. Acute myelogenous leukemia blasts as accessory cells during T cell activation
28. Cytokine responsiveness of mitogen-activated T cells derived from acute leukemia patients with chemotherapy-induced leukopenia
29. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: Studies of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin 3 (IL3) and Flt3-ligand (Flt3-L)
30. The cellular immune system of patients with acute leukemia and severe chemotherapy-induced leukopenia: Characterization of T lymphocyte subsets responsive to IL16 and IL17
31. Soluble Fas/Apo-1 (CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variations in systemic levels
32. Functional studies with anti-CD3 isotype switch-variant monoclonal antibodies. Accessory cell independent induction of interleukin 2 responsiveness in T cells by ε-anti-CD3
33. A simple, robust, validated and highly predictive index for the determination of risk-adapted therapy in acute myeloid leukemia derived from the MRC AML 10 trial
34. New strategies in the treatment of acute myelogenous leukemia: Differentiation induction - Present use and future posssibilities
35. Mechanisms of growth factor expression in acute myeloid leukemia (AML)
36. Effects of interferon γ on the expression of interferon α, interleukin 6, granulocyte-macrophage-colony stimulating factor and tumor necrosis factor α in acute myeloid leukemia blasts
37. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: An analysis of the EORTC-GINEMA AML 8A trial
38. Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission
39. The pathophysiology of tumor necrosis factors
40. Interleukin 1 and interleukin 1 antagonism
41. The biology of interleukin 6
42. ARDS network, Ketokonazole for early treatment of acute lung injury and acute respiratory distress syndrome: A randomized controlled trial
43. Serum itraconazole concentrations and clinical responses in Candida-associated denture stomatitis patients treated with itraconazole solution and itraconazole capsules
44. High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection
45. Surveillance of the serum Candida antigen titer for initiation of antifungal therapy after postremission chemotherapy in patients with acute leukemia
46. Bioassays for itraconazole blood levels: An interlaboratory collaborative study